The standard Johns Hopkins' regimen will be used in study subjects, with the use of donor
peripheral blood stem cells, rather than marrow. Clinical outcomes will be defined while
focusing efforts on immune reconstitution focusing on immune checkpoint regulators after a
related haploidentical stem cell transplant.